Responding to Observations - - BioPharm International

ADVERTISEMENT

Responding to Observations


BioPharm International


Responding to observations made by inspectors is often the most difficult part of completing the inspection process. But it is critical at this stage to remember the potential benefits that can result from an audit — better and more frequent employee training and more efficient operation, documentation, process improvements, and new scientific and technological advances. With these long-term benefits in mind, you and your team can tackle the postinspection process with energy and confidence.

The Last Day of the AuditOn the last day of the inspectors' visit, executives are given an opportunity to defend the deficiencies cited by inspectors. Inspectors will listen to any defense offered by the management team before formally issuing the citations or the list of 483s (483 is the number assigned to the form that includes the citations found by FDA inspectors). During the process, avoid conflict, and do not become too emotionally involved. This is a second chance to present the facts objectively.

Use this opportunity to understand clearly what the citations are and what the inspectors intend to convey to you in the citation. Ask questions such as, "Do you mean that our procedures are inadequate?" and "Do you think we need more training in this area?" Responses to this type of question will help you clarify what the inspectors expect in remediation.

Developing a ResponseOnce the final observations have been issued, the clock begins to tick. FDA will expect a response within 10 to 15 working days.

Form a committee that includes, at minimum, members of the quality assurance (QA) and regulatory affairs departments. Put as many people on the committee as you like, but the best committee includes the most qualified members of each department and maintains an environment in which topics can be discussed openly and decisions made easily.

It is the committee's responsibility to review and clearly understand the observations made by FDA. The terminology can be confusing, so this is an excellent time to clear up any confusion and determine what needs to be done. It is also a chance to determine whether the observation is isolated or is the result of a bigger issue or trend that might be occurring.

Subcommittees. As the committee evaluates each observation, it should create subcommittees to investigate and respond to observations. Many times an investigation is the only way to discover why an observation was made. For instance, research and development might provide time and temperature specifications used for a drug recipe in the manufacturing process. If the time and temperature specifications are questioned during the inspection, and the manufacturing division never questioned those requirements, the investigation subcommittee will work with research and development to determine the rationale for developing the specifications in the first place and communicate it to all departments.

Response document. When developing a response, many companies make the mistake of writing general statements to address an observation. Responses such as "We will try harder next time" or "We will fix this SOP" are unacceptable. Responses should be as specific as possible. If there is more than one part to the observation, a separate response must be written for each section.

In each response, indicate whether the observation is an isolated incident or a global issue. For example, an inspector might notice a deficiency in the documentation process in which a validation package is lacking one specific element. It is the responsibility of the committee to determine whether this was simply an isolated incident in the documentation of that specific validation package or a general practice in which all validation packages lack that element.

When developing a response provide a corrective action plan to remedy the observation. Establish why you think the corrective action will resolve the situation, and create a mechanism — such as a new SOP that controls and monitors the steps — to show that this problem has been corrected and will not occur again.

Provide a timetable for the completion of the corrective action plan, and make someone responsible for enforcing it. Be realistic about how long it will take you to solve the problem. Generally, people in a state of panic do not realize what they are committing to until after they've made the commitment. Making promises you can't keep can lead to noncompliance in the future. So create a realistic timetable; and depending on the issue, establish a long-term program within the timetable. Also, include in the timetable a proper training program, and ensure that department managers agree to meet specific deadlines.

If you disagree with an observation, make sure your response is based on facts and has verifiable data and documentation as supporting evidence. Present your evidence as clearly as possible.


Validation from Past to Future
After each observation is studied carefully and appropriate corrective actions with proper deadlines are agreed on, prepare a detailed response document. List each observation with the proper responses separately. Avoid general responses such as "All the above citations will be resolved by . . ." Instead, list each item separately, and assign separate completion dates for each.

Follow-UpAfter submitting your response to FDA, several months may pass before the agency replies. Do not wait for FDA to respond before implementing your action plan; start work immediately. If the agency disagrees with the steps you have listed, then adjustments can be made later. Inspectors always consider what steps have been taken in good faith to resolve the issue, and they will be more sympathetic if some corrective action has been started. Begin resolving the problem as soon as possible — don't wait until told to do so.

Assign an internal committee to monitor the progress of each corrective action. This can be the same management team that developed the original response, but make sure they have the authority to monitor the progress.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

EMA Warns of Falsified Herceptin Vials
April 16, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Author Guidelines
Source: BioPharm International,
Click here